Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

8.98
-0.6000-6.26%
Post-market: 8.980.00000.00%19:34 EDT
Volume:135.14K
Turnover:1.23M
Market Cap:313.25M
PE:-9.18
High:9.88
Open:9.71
Low:8.92
Close:9.58
52wk High:16.76
52wk Low:8.92
Shares:34.88M
Float Shares:18.45M
Volume Ratio:1.09
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9783
EPS(LYR):-0.9800
ROE:-33.21%
ROA:-22.67%
PB:1.77
PE(LYR):-9.16

Loading ...

Feb 13, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 13, 2023

Major Issues Report

8-K - Current report
Feb 08, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 23, 2023

Major Issues Report

8-K - Current report
Dec 15, 2022

Correspondence

CORRESP [Cover] - Correspondence
Dec 13, 2022

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Dec 12, 2022

Major Issues Report

8-K - Current report
Dec 08, 2022

Major Issues Report

8-K - Current report
Nov 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2022

Major Issues Report

8-K - Current report
Oct 18, 2022

Major Issues Report

8-K - Current report
Oct 11, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Oct 07, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Sep 23, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Sep 16, 2022

Major Issues Report

8-K - Current report
Sep 12, 2022

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Sep 09, 2022

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Sep 08, 2022

Correspondence

CORRESP [Cover] - Correspondence
Sep 08, 2022

Correspondence

CORRESP [Cover] - Correspondence
Sep 07, 2022

Major Issues Report

8-K - Current report